Advertise on podcast: Future Science Group

First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study by Taylor & Francis Group

In this podcast episode, the speakers discuss how the findings from the EMBARK clinical trial could translate into real world practice.

This podcast focuses on the real-world implications of these EMBARK findings for clinical practice.

This podcast features two of the investigators from the international, randomized, Phase III EMBARK trial (NCT02319837) in conversation. EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen deprivation therapy alone, in patients with nonmetastatic castration-sensitive prostate cancer and biochemical recurrence at high risk for metastasis. In this podcast, the second in the EMBARK series, the speakers discuss the key efficacy and safety findings from the trial, consider some of the patient-reported outcomes and their implications for quality of life, and review some of the implications for clinical practice.

In this interview, discover discuss key findings from the DESTINY-Breast09 trial and their implications for clinical practice, including practical advice for oncologists exploring treatment sequencing strategies with T-DXd.

Meet Giorgi Kobidze, your 2026 BRSA finalist.

Meet Richa Pandey, your 2026 BRSA finalist.

Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study by Taylor & Francis Group

Meet Dakshat Trivedi, your 2026 BRSA finalist.

Meet Ethan Sanford, your 2026 BRSA finalist.

Harmonizing scientific innovation, patient care and regulation in advanced therapies: a podcast with Patrice Faloye by Taylor & Francis Group

In this podcast, Deborah Ojutalayo discusses targeted gene therapies for frontotemporal dementia caused by mutations in the GRN gene.

In this podcast, Guillermo explores the development and diverse applications of citrate-based biomaterials, pioneered by his lab, Ameer Labs. He highlights the versatility and potential of these biomaterials, providing examples such as their use in bone and cartilage regeneration. Guillermo also delves into exciting advancements in tissue and regenerative engineering that aim to address significant challenges in the field.

In this podcast, Baba delves into his expertise in hematology, sharing what inspired his journey into this field of research. He also discusses the Academy for Sickle Cell and Thalassaemia (ASCAT) Conference, which he founded to unite experts and professionals working to tackle hematological disorders like sickle cell disease and thalassemia.

Hello and welcome to the latest episode of OCTalks, the podcast series from Oncology Central. I am Jade Parker, Senior Editor of Oncology Central. Today I am joined by Leanne Bailey who is Branch Director of the Community Outreach Research and Engagement branch of the NCI’s Center to Reduce Cancer Health Disparities. In this interview, we will discuss contributing factors to early onset cancers, how are certain groups disproportionately affected and initiatives that are seeking to reduce disparities in cancer care. Thank you for joining us, LeeAnn.